OBJECTIVES: To determine whether early damage and its kinetics measured by the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality. METHODS: We carried out a single-centre retrospective analysis of thrombotic APS patients (2006 Sydney criteria), using the DIAPS for damage assessment. Early damage was considered to be at six months after disease onset; early damage increase (delta-DIAPS) was deemed to be at least a one-point rise in DIAPS within the first five years of illness. Groups were compared using appropriate statistical tests. Survival was analysed by the Kaplan-Meier method. Cox regression analysis was performed to investigate predictors of mortality. RESULTS: A total of 197 patients (71.1% female; 65.9% primary AP...
Objective: To assess the prevalence of disease- and therapy-related complications and of the organ d...
Objectives To validate the performance of the adjusted global antiphospholipid syndrome (APS) score ...
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
INTRODUÇÃO: A síndrome antifosfolípide (SAF) é uma trombofilia adquirida que afeta indivíduos jovens...
The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4 % to 5.5 %, but its predic...
OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
The antiphospholipid antibody syndrome (APS), a chronic autoimmune thrombophilia with an increased m...
Objective. To describe morbidity, organ damage, mortality, and cause of death in patients with antip...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4 % to 5.5 %, but its predic...
Objective: To assess the prevalence of disease- and therapy-related complications and of the organ d...
Objectives To validate the performance of the adjusted global antiphospholipid syndrome (APS) score ...
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
INTRODUÇÃO: A síndrome antifosfolípide (SAF) é uma trombofilia adquirida que afeta indivíduos jovens...
The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4 % to 5.5 %, but its predic...
OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
The antiphospholipid antibody syndrome (APS), a chronic autoimmune thrombophilia with an increased m...
Objective. To describe morbidity, organ damage, mortality, and cause of death in patients with antip...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid...
Objectives: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid s...
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid...
The vascular mortality of antiphospholipid syndrome (APS) ranges from 1.4 % to 5.5 %, but its predic...
Objective: To assess the prevalence of disease- and therapy-related complications and of the organ d...
Objectives To validate the performance of the adjusted global antiphospholipid syndrome (APS) score ...
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid...